“Global Enteral Syringe Market to reach a market value of 556.9 million by 2031 growing at a CAGR of 5.1%”
The Global Enteral Syringe Market size is expected to reach $556.9 million by 2031, rising at a market growth of 5.1% CAGR during the forecast period.
The prevalence of chronic diseases, such as cancer and cardiovascular conditions, is on the rise in the Asia-Pacific region. These conditions often require enteral feeding, increasing the demand for these syringes. Patients with chronic illnesses may need long-term nutritional support, which can be effectively managed using these syringes. Consequently, the Asia Pacific region would acquire nearly 30% of the total market share by 2031.
Adopting nutritional support therapy emphasizes personalized care tailored to individual patient needs. In addition, updated clinical guidelines and protocols now commonly include recommendations for nutritional support therapy as a standard practice for managing patients with specific health conditions. Hence, the increasing adoption of nutritional support therapy is driving the market’s growth.
Additionally, Older adults frequently experience health conditions that necessitate specialized nutritional support. Conditions such as malnutrition, dysphagia (difficulty swallowing), and chronic illnesses often require enteral feeding solutions. Additionally, chronic diseases like diabetes, heart disease, and cancer are more common among the elderly population. Thus, the growing aging population is propelling the growth of the market.
However, Healthcare facilities, particularly those operating under tight budget constraints, may struggle to justify the expenditure on advanced syringes. Patients, especially those in lower-income brackets or regions with limited healthcare funding, may have restricted access to advanced syringes due to their high cost. In conclusion, the high cost of advanced syringes hampers the market’s growth.
Moreover, the postponement of elective medical procedures and treatments during the pandemic decreased the need for these syringes in certain healthcare settings. The overwhelming pressure on healthcare facilities due to the COVID-19 crisis disrupted routine care and management of patients requiring enteral feeding. Major industry events, trade shows, and conferences were cancelled or held virtually, limiting networking and market growth opportunities. Thus, the COVID-19 had a negative impact on the market.
On the basis of age group, the market is segmented into adults and paediatrics. In 2023, the paediatrics segment attained 23% revenue share in the market. Advances in medical care have significantly improved the survival rates of preterm infants and children with severe health conditions, many of whom require enteral feeding.
By end user, the market is divided into hospitals, ambulatory surgical centres, and homecare. The homecare segment procured a 13% revenue share in the market in 2023. As the global population ages, more elderly individuals require long-term care, including enteral feeding, which can be effectively managed at home using these syringes.
Based on type, the market is divided into reusable and disposable. The reusable segment procured 37% revenue share in the market in 2023. Although reusable syringes require an initial investment, they can be more cost-effective over time than disposable syringes. For healthcare facilities with high usage rates, the cumulative cost of disposables can be significantly higher.
Free Valuable Insights: Global Enteral Syringe Market size to reach USD 556.9 Million by 2031
Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region witnessed a 35% revenue share in the market in 2022. North America boasts a sophisticated healthcare system with numerous hospitals, clinics, and long-term care facilities equipped with advanced medical technologies, including these syringes.
| Report Attribute | Details |
|---|---|
| Market size value in 2023 | USD 378.6 Million |
| Market size forecast in 2031 | USD 556.9 Million |
| Base Year | 2023 |
| Historical Period | 2020 to 2022 |
| Forecast Period | 2024 to 2031 |
| Revenue Growth Rate | CAGR of 5.1% from 2024 to 2031 |
| Number of Pages | 226 |
| Number of Tables | 330 |
| Report coverage | Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Porter’s 5 Forces Analysis, Company Profiling, Companies Strategic Developments, SWOT Analysis, Winning Imperatives |
| Segments covered | Age Group, Type, End User, Region |
| Country scope |
|
| Companies Included | Boston Scientific Corporation, Nestlé S.A., Fresenius SE & Co. KGaA, Becton, Dickinson and Company, B. Braun Melsungen AG, Cardinal Health, Inc., Moog Inc., Cook Medical, Inc. (Cook Group), Thermo Fisher Scientific Inc. and Medela AG |
By Age Group
By End User
By Type
By Geography
This Market size is expected to reach $556.9 million by 2031.
Increasing adoption of nutritional support therapy are driving the Market in coming years, however, High cost of advanced enteral syringes restraints the growth of the Market.
Boston Scientific Corporation, Nestlé S.A., Fresenius SE & Co. KGaA, Becton, Dickinson and Company, B. Braun Melsungen AG, Cardinal Health, Inc., Moog Inc., Cook Medical, Inc. (Cook Group), Thermo Fisher Scientific Inc. and Medela AG
The expected CAGR of this Market is 5.1% from 2024 to 2031.
The Hospitals segment led the Market by End User in 2023; thereby, achieving a market value of $342 Million by 2031.
The North America region dominated the Market by Region in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $187 Million by 2031.
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 